Literature DB >> 23017140

Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.

Gary Kohanbash1, Hideho Okada.   

Abstract

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of cells that inhibit anti-tumor immunity through a variety of mechanisms. Malignant gliomas are heavily infiltrated by myeloid cells, some of which appear to share biological functions of MDSCs. Our data with mouse de novo gliomas indicate critical roles of these cells in glioma development. This review summarizes the current understanding of MDSC biology in gliomas and discusses therapeutic interventions that can safely reverse the suppressive effects of MDSCs. The insight gained from these findings may lead to the development of novel immunotherapeutic strategies for gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017140     DOI: 10.3109/08820139.2012.689591

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  30 in total

Review 1.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

2.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

3.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

4.  Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma.

Authors:  Susan Brandenburg; Kati Turkowski; Annett Mueller; Yordan T Radev; Sabine Seidlitz; Peter Vajkoczy
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

5.  Glioblastoma: Defining Tumor Niches.

Authors:  Dolores Hambardzumyan; Gabriele Bergers
Journal:  Trends Cancer       Date:  2015-12

6.  Malignant Glial Neuronal Tumors After West Nile Virus Neuroinvasive Disease: A Coincidence or a Clue?

Authors:  Akanksha Sharma; Marie F Grill; Scott Spritzer; A Arturo Leis; Mark Anderson; Parminder Vig; Alyx B Porter
Journal:  Neurohospitalist       Date:  2018-12-26

7.  Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.

Authors:  Alba Gonzalez-Junca; Oliver Reiners; Luis D Borrero-Garcia; Denis Beckford-Vera; Ann A Lazar; William Chou; Steve Braunstein; Henry VanBrocklin; Benjamin L Franc; Mary Helen Barcellos-Hoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-29       Impact factor: 7.038

8.  Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.

Authors:  Sören Müller; Sameer Agnihotri; Karsen E Shoger; Max I Myers; Nicholas Smith; Srilakshmi Chaparala; Clarence R Villanueva; Ansuman Chattopadhyay; Adrian V Lee; Lisa H Butterfield; Aaron Diaz; Hideho Okada; Ian F Pollack; Gary Kohanbash
Journal:  JCI Insight       Date:  2018-04-05

9.  GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

Authors:  Gary Kohanbash; Kayla McKaveney; Masashi Sakaki; Ryo Ueda; Arlan H Mintz; Nduka Amankulor; Mitsugu Fujita; John R Ohlfest; Hideho Okada
Journal:  Cancer Res       Date:  2013-09-12       Impact factor: 12.701

10.  Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.

Authors:  Shubhanchi Nigam; Lauren McCarl; Rajeev Kumar; Robert S Edinger; Brenda F Kurland; Carolyn J Anderson; Ashok Panigrahy; Gary Kohanbash; W Barry Edwards
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.